Patients with anti-GBM disease combined with mesangial IgA deposition have less incidence of oliguria or anuria, lower SCr levels at diagnosis, and better renal outcomes than patients with the classical anti-GBM disease, which indicates less impairment of kidney function. This evidence concerns the gene CD79A and glioblastoma.